Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
作者信息
Psallas M, Manes C
机构信息
Diabetic Center, Papageorgiou Teaching Hospital, Thessaloniki, Greece.
出版信息
Hippokratia. 2012 Apr;16(2):100-5.
Abstract
Type 2 diabetes mellitus is the most outspreading disease of the western world and it provides cardiovascular disease. During the past decade new drug categories were added to the already existing ones. Perhaps, the most outstanding, as promising, too, are glucagon-like peptide-1(GLP-1) analogues, which pinpointed at the incretin hormone system, targeting mainly at the postprandial hyperglycemia.It seemed that these novel drugs have beneficial effects on ischemic heart, heart failure,blood pressure, even on lipids and body weight in type 2 diabetics, considering them not only as another glucose lowering agent. A lot of recent studies investigate the potential relationship between GLP-1 and its possible cardioprotective and anti-atherogenic effects in type 2 diabetes and the present review discusses these effects of GLP-1.
摘要
相似文献
1
Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
Hippokratia. 2012 Apr;16(2):100-5.
2
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
Expert Opin Investig Drugs. 2009 Oct;18(10):1495-503. doi: 10.1517/14728220903241633.
3
Blood pressure-lowering effects of incretin-based diabetes therapies.
Can J Diabetes. 2014 Oct;38(5):364-71. doi: 10.1016/j.jcjd.2014.05.001.
4
Cardiovascular biology of the incretin system.
Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8.
5
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
6
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Diabetes Obes Metab. 2016 Sep;18(9):847-54. doi: 10.1111/dom.12685. Epub 2016 Jun 7.
7
Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25.
8
Understanding the cardiovascular effects of incretin.
Diabetes Metab J. 2011 Oct;35(5):437-43. doi: 10.4093/dmj.2011.35.5.437. Epub 2011 Oct 31.
9
Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21.
10
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
引用本文的文献
1
Benefits of Whey Proteins on Type 2 Diabetes Mellitus Parameters and Prevention of Cardiovascular Diseases.
Nutrients. 2023 Mar 6;15(5):1294. doi: 10.3390/nu15051294.
2
The Evaluation of Dipeptidyl Peptidase (DPP)-IV, α-Glucosidase and Angiotensin Converting Enzyme (ACE) Inhibitory Activities of Whey Proteins Hydrolyzed with Serine Protease Isolated from Asian Pumpkin ().
Int J Pept Res Ther. 2014;20(4):483-491. doi: 10.1007/s10989-014-9413-0. Epub 2014 Jun 1.
本文引用的文献
1
Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes.
Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9. doi: 10.1097/01.hjr.0000368193.24732.66.
2
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.
Cardiovasc Diabetol. 2010 Jan 28;9:6. doi: 10.1186/1475-2840-9-6.
3
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
Expert Opin Investig Drugs. 2009 Oct;18(10):1495-503. doi: 10.1517/14728220903241633.
4
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
Circ Heart Fail. 2008 Sep;1(3):153-60. doi: 10.1161/CIRCHEARTFAILURE.108.766402.
5
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Diabetologia. 2009 Oct;52(10):2046-55. doi: 10.1007/s00125-009-1472-y. Epub 2009 Aug 14.
6
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.
BMC Cardiovasc Disord. 2009 Jul 23;9:31. doi: 10.1186/1471-2261-9-31.
7
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.
8
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.
9
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.
10
Glucose normalization and outcomes in patients with acute myocardial infarction.
Arch Intern Med. 2009 Mar 9;169(5):438-46. doi: 10.1001/archinternmed.2008.593.
Zotero 插件